For example, the following ADCs have been approved by the FDA for the treatment of breast cancer: Kadcyla® (ado-trastuzumab emtansine) and Enhertu® (fam-trastuzumab deruxtecan-nxki), target antigen for which is HER2; and Trodelvy® (sacituzumab govitecan-hziy), the target antigen for which is Trop-2. This evidence concerns the gene ERBB2 and breast carcinoma.